For the Quarter Ending June 2026
Orlistat Prices in North America
- In the United States, the Orlistat Price Index rose in Q2 2026, driven by surging demand for weight loss medications.
- Orlistat production costs increased in June 2026, as the Producer Price Index climbed 5.5% year-over-year.
- Demand for weight loss medications, including Orlistat, surged mid-2026, supported by strong US pharmaceutical market growth.
- Consumer purchasing power eroded in June 2026 due to a 3.5% year-over-year rise in the Consumer Price Index.
- Orlistat demand outlook remained positive in Q2 2026, bolstered by 6.9% retail sales growth in May 2026.
- A low 4.2% unemployment rate in June 2026 supported consumer confidence and health product spending.
- Natural gas prices inched up slightly in Q2 2026, increasing production costs for Orlistat.
- US industrial production growth was low at 0.7% year-over-year in June 2026, affecting manufacturing inputs.
Why did the price of Orlistat change in June 2026 in North America?
- Orlistat demand surged mid-2026 from increased GLP-1 usage and robust retail sales in May 2026.
- Production costs for Orlistat rose in June 2026, influenced by a 5.5% year-over-year Producer Price Index increase.
- Strong consumer spending, indicated by a 4.2% unemployment rate in June 2026, supported demand.
Orlistat Prices in APAC
- In China, the Orlistat Price Index rose quarter-over-quarter in Q2 2026, driven by rising costs and robust API demand. The Average price of the Orlistat Price stood at USD 455520/MT FOB China.
- Orlistat production costs increased in Q2 2026, influenced by a 4.1% rise in producer prices in June 2026.
- Orlistat demand outlook strengthened, supported by robust API market growth and healthcare spending in Q2 2026.
- The Manufacturing Index expanded in June 2026, indicating increased production capacity for Orlistat.
- Industrial production grew by 5.3% year-over-year in June 2026, bolstering economic activity and Orlistat demand.
- Consumer prices remained stable with 1.0% CPI and 5.0% unemployment in June 2026, supporting purchasing power.
- Brent crude oil prices softened in June 2026, while natural gas costs declined in Q2 2026, easing energy inputs.
- Pharmaceutical exports from China slightly weakened between April and May 2026, impacting trade flows.
- Elevated general chemical inventories in China during Q2 2026 contributed to increased export volumes.
Why did the price of Orlistat change in June 2026 in APAC?
- Rising producer prices, up 4.1% in June 2026, increased raw material and manufacturing costs.
- Robust API market growth and strengthening healthcare spending in Q2 2026 bolstered demand.
- Subdued retail sales growth of 1.0% in June 2026 tempered discretionary Orlistat demand.
Orlistat Prices in Europe
- In Germany, the Orlistat Price Index rose in Q2 2026, driven by increased production costs and strengthening demand.
- Orlistat production costs increased in Q2 2026, as producer prices for industrial products rose by 2.2% in May 2026.
- Demand for anti-obesity drugs strengthened in Germany during Q2 2026, propelled by patient adoption of advanced therapies.
- Raw material and transportation costs for the chemical and pharmaceutical industry climbed sharply in Q2 2026.
- Industrial production in Germany was unchanged at 0.0% in May 2026, while the Manufacturing Index contracted in June 2026.
- Consumer spending supported Orlistat demand, with retail sales increasing by 1.8% in May 2026.
- Industry inventories tightened in Q2 2026, due to precautionary stockpiling amidst escalating geopolitical tensions.
Why did the price of Orlistat change in June 2026 in Europe?
- Rising production costs, with PPI increasing 2.2% in May 2026, directly impacted Orlistat manufacturing expenses.
- Strengthening demand for anti-obesity drugs in Q2 2026, coupled with tightening inventories, exerted upward price pressure.
- Elevated energy costs and sharp increases in raw material and transportation expenses in Q2 2026 contributed to higher operational burdens.
For the Quarter Ending March 2026
Orlistat Prices in North America
- In United States, the Orlistat Price Index rose quarter-over-quarter in Q1 2026, driven by elevated production costs.
- The Orlistat Production Cost Trend increased in March 2026 as producer prices rose 4.0% year-over-year.
- Retail sales grew 4.0% year-over-year in March 2026, while consumer inflation reached 3.3%, impacting pharmacy pricing.
- The Orlistat Demand Outlook strengthened in March 2026, supported by 4.3% unemployment and 91.8 consumer confidence.
- Industrial production grew 0.7% year-over-year in March 2026, and the Manufacturing Index expanded, ensuring supply stability.
- Soybean meal fermentation feedstock costs for Orlistat strengthened in February 2026, directly elevating synthesis expenses.
- United States soybean fermentation feedstock inventories stabilized in March 2026, while import volumes strengthened simultaneously.
- Soybean meal fermentation feedstock export volumes surged in February 2026, alongside strengthening domestic feed consumption.
- The Orlistat Price Forecast reflected an upward trajectory throughout Q1 2026 due to sustained cost-push dynamics.
Why did the price of Orlistat change in March 2026 in North America?
- Producer prices rose 4.0% year-over-year in March 2026, directly increasing active pharmaceutical ingredient synthesis expenses.
- Soybean meal fermentation feedstock costs strengthened in February 2026, adding significant pressure to manufacturing operations.
- Retail sales grew 4.0% year-over-year in March 2026, sustaining robust consumer purchasing power at pharmacies.
Orlistat Prices in APAC
- In China, the Orlistat Price Index rose quarter-over-quarter in Q1 2026, driven by strengthening feedstock costs.
- A mild Consumer Price Index increase of 1.0% in March 2026 supported a steady Orlistat Demand Outlook.
- The Producer Price Index rose 0.5% in March 2026, directly elevating the Orlistat Production Cost Trend.
- Industrial production grew 5.7% in March 2026, ensuring robust supply availability for the pharmaceutical manufacturing sector.
- Retail sales grew 1.7% and unemployment reached 5.4% in March 2026, dampening consumer discretionary spending.
- The consumer confidence index hit 91.6 in February 2026, negatively impacting the OTC weight-loss medication market.
- The Manufacturing Index expanded in March 2026, indicating healthy production rates for fine chemical precursors.
- The Orlistat Price Forecast reflected upward pressures from strengthened soybean meal fermentation feedstock costs in Q1 2026.
- Healthcare reforms and rising obesity rates bolstered prescription weight management drug adoption throughout Q1 2026.
Why did the price of Orlistat change in March 2026 in APAC?
- Imported soybean meal fermentation feedstock costs strengthened due to higher freight expenses in Q1 2026.
- The Producer Price Index rose 0.5% in March 2026, increasing factory-gate prices for chemical precursors.
- Broader energy costs and transportation logistics expenses surged significantly amid geopolitical tensions in Q1 2026.
Orlistat Prices in Europe
- In Germany, the Orlistat Price Index rose quarter-over-quarter in Q1 2026, driven by surging pharmaceutical manufacturing costs.
- The Orlistat Production Cost Trend increased during March 2026 as the CPI rose by 2.7% year-over-year.
- Despite the overall PPI declining 0.2% in March 2026, pharmaceutical manufacturing producer prices surged in February 2026.
- Industrial production remained flat at 0.0% in February 2026, while overall pharmaceutical production growth decelerated in January 2026.
- Retail sales contracted 2.0% in March 2026, yet the Orlistat Demand Outlook expanded robustly throughout Q1 2026.
- The unemployment rate held at 4.0% in February 2026, while consumer confidence dropped to -13.9 points in March 2026.
- The Manufacturing Index expanded in March 2026, and soybean and glycerine feedstock costs stabilized during Q1 2026.
- Pharmaceutical export flows tightened in Q1 2026, which influenced the upward Orlistat Price Forecast during March 2026.
Why did the price of Orlistat change in March 2026 in Europe?
- Regional demand for anti-obesity medications expanded during Q1 2026, driving strong upward market pricing pressure.
- Pharmaceutical manufacturing producer prices surged in February 2026, directly elevating the overall production cost burdens.
- Crude oil benchmarks strengthened in January 2026, impacting the broader chemical logistics and transportation expenses.
For the Quarter Ending December 2025
Orlistat Prices in North America
- In United States, Orlistat Price Index rose in Q4 2025, driven by increased production costs.
- Orlistat production costs increased in Q4 2025, as industrial electricity costs rose in November 2025.
- Rising input costs for the pharmaceutical sector were indicated by a 3.0% year-over-year PPI increase in November 2025.
- General inflation, with a 2.7% year-over-year CPI increase in December 2025, raised raw material costs.
- Orlistat demand outlook was supported by a 3.3% year-over-year increase in retail sales in November 2025.
- Consumer spending on health products was bolstered by a 4.4% unemployment rate in December 2025.
- A 2.0% year-over-year increase in industrial production in December 2025 indirectly supported Orlistat supply chains.
- Orlistat price trends in Q4 2025 reflected ongoing inflationary pressures and robust consumer demand.
Why did the price of Orlistat change in December 2025 in North America?
- Rising input costs, with a 2.7% year-over-year CPI increase in December 2025, elevated production expenses.
- Strong consumer spending, supported by a 4.4% unemployment rate in December 2025, boosted Orlistat demand.
- Natural gas spot prices gradually rose in December 2025, contributing to increased energy feedstock costs.
Orlistat Prices in APAC
- In China, the Orlistat Price Index fell quarter-over-quarter in Q4 2025, influenced by weak consumer demand.
- Orlistat production costs declined in December 2025, as producer prices fell by 1.9% year-over-year.
- The Manufacturing Index expanded in December 2025, supporting a robust supply chain for Orlistat production.
- Industrial production grew by 5.2% year-over-year in December 2025, ensuring stable raw material supply for Orlistat.
- Orlistat demand outlook was subdued in Q4 2025 due to decelerated economic growth and 0.9% retail sales growth.
- New chemical capacity emerged in China in 2025, intensifying competition and impacting Orlistat pricing.
- Demand for pharmaceutical products, particularly weight management, showed expansion in China in 2025.
- Consumer sentiment cooled in Q4 2025, contributing to cautious spending on discretionary health products.
Why did the price of Orlistat change in December 2025 in APAC?
- Producer prices declined by 1.9% year-over-year in December 2025, reducing Orlistat manufacturing costs.
- Weak consumer demand, with 0.8% CPI and 0.9% retail sales growth in December 2025, pressured Orlistat prices.
- New chemical capacity and persistent overcapacity in the broader chemical sector intensified competition in 2025.
Orlistat Prices in Europe
- In Germany, the Orlistat Price Index remained stable quarter-over-quarter in Q4 2025, supported by 1.8% CPI in December 2025.
- Orlistat production costs declined in December 2025, as producer prices fell by 2.5% year-over-year.
- Industrial energy and natural gas prices for industrial customers weakened in Germany during December 2025.
- Orlistat demand outlook faced challenges in December 2025 due to a contracting Manufacturing Index.
- Consumer confidence at -17.5 in December 2025 impacted discretionary OTC Orlistat spending.
- Retail sales grew by 1.1% year-over-year in November 2025, offering some support for OTC Orlistat demand.
- The unemployment rate of 6.2% in December 2025 reduced consumer purchasing power for health products.
- Germany's pharmaceutical market experienced moderate growth in 2025, supporting overall Orlistat demand.
- Trade barriers, including US tariff policy, negatively impacted German chemical companies' US business in 2025.
- Orlistat Price Index forecast suggests continued stability, balancing lower costs with cautious consumer spending.
Why did the price of Orlistat change in December 2025 in Europe?
- Producer prices decreased by 2.5% year-over-year in December 2025, reducing Orlistat manufacturing costs.
- Consumer confidence at -17.5 in December 2025 dampened demand for discretionary OTC Orlistat.
- Industrial energy and natural gas prices weakened in Germany during December 2025, lowering operational expenses.
For the Quarter Ending September 2025
Orlistat Prices in North America
- In United States, the Orlistat Price Index remained stable quarter-over-quarter in Q3 2025, balancing demand and cost factors.
- Orlistat production costs faced upward pressure from a 2.6% PPI increase in August 2025 for manufacturing inputs.
- Hexane feedstock costs moved lower in Q3 2025, driven by consistent refining operations and softened downstream intake.
- Demand for weight-loss drugs, including GLP-1 analogues, showed significant growth in 2025, supporting Orlistat market.
- Robust US retail sales, up 5.42% in September 2025, bolstered consumer spending despite weakened consumer confidence.
- A low 4.3% unemployment rate in September 2025 supported disposable income and access to health insurance.
- The global chemicals industry experienced tight margins and overcapacity in Q3 2025, affecting overall market dynamics.
- US chemical production contracted in Q3 2025, reflecting broader industrial sluggishness with minimal industrial production growth.
- Orlistat Price Forecast suggests continued stability, balancing cost pressures with sustained demand for weight management solutions.
Why did the price of Orlistat change in September 2025 in North America?
- Producer prices increased 2.6% in August 2025, raising Orlistat manufacturing input costs.
- Robust US retail sales, up 5.42% in September 2025, supported demand for health products.
- Hexane feedstock costs declined in Q3 2025, partially offsetting other production cost increases.
Orlistat Prices in APAC
- In China, the Orlistat Price Index fell quarter-over-quarter, influenced by deflationary pressures and global oversupply in Q3 2025.
- Orlistat production costs were influenced by falling factory-gate prices (PPI -2.3% YoY) and steady petrochemical feedstock costs.
- Domestic pharmaceutical demand strengthened in Q3 2025, driven by an aging population and increasing chronic diseases.
- Overall domestic consumption showed weakness in Q3 2025, despite 3.0% year-on-year retail sales growth.
- China's industrial production increased 6.5% year-on-year in September 2025, supporting stable supply chains.
- The Manufacturing Index was contracting in September 2025, indicating a slowdown in broader industrial activity.
- Consumer confidence stood at 89.6 in September 2025, reflecting pessimism and reduced discretionary spending.
- Global oversupply in the chemicals market persisted in Q3 2025, with China adding significant chemical capacity.
- The pharmaceutical intermediate sector in China expanded steadily in Q3 2025, driven by cost-effective manufacturing.
Why did the price of Orlistat change in September 2025 in APAC?
- Deflationary pressures (CPI -0.3% YoY September 2025) dampened consumer purchasing power.
- A contracting Manufacturing Index in September 2025 signaled economic weakness and impacted supply chains.
- Global oversupply in the chemicals market, coupled with China's capacity additions, exerted downward pressure.
Orlistat Prices in Europe
- In Germany, the Orlistat Price Index fell quarter-over-quarter in Q3 2025, influenced by a 1.7% decline in producer prices.
- Orlistat production costs in Q3 2025 saw mixed trends from eased natural gas, but elevated electricity and carbon costs.
- Orlistat demand outlook in Q3 2025 was tempered by significantly negative consumer confidence (-23.6 index).
- A contracting Manufacturing Index and 1.0% industrial production decline in September 2025 impacted Orlistat supply.
- Low unemployment (3.9%) in September 2025 supported Orlistat demand by bolstering consumer purchasing power.
- Germany's pharmaceutical market expanded in Q3 2025, providing a stable demand base for Orlistat.
- Rising CPI (2.4%) in September 2025 signaled higher operational costs for Orlistat producers.
- Modest retail sales growth (0.8%) in September 2025 indicated cautious spending on discretionary Orlistat.
Why did the price of Orlistat change in September 2025 in Europe?
- Producer prices (PPI) declined by 1.7% in September 2025, reducing Orlistat input costs.
- Consumer confidence was significantly negative (-23.6 index) in September 2025, dampening Orlistat demand.
- Elevated electricity prices for businesses in Q3 2025 increased Orlistat manufacturing operational costs.
